Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2011.00869.x/abstract

Longitudinal assessment of liver stiffness by transient elastography for chronic

hepatitis B patients treated with nucleoside analog

Eiichi Ogawa1, Norihiro Furusyo1,2,*, Masayuki Murata1, Hachiro Ohnishi1,

Kazuhiro Toyoda1, Hiroaki Taniai1, Takeshi Ihara2, Hiroaki Ikezaki2, Takeo

Hayashi2, Mosaburo Kainuma1, Jun Hayashi1,2

Article first published online: 15 SEP 2011

DOI: 10.1111/j.1872-034X.2011.00869.x

© 2011 The Japan Society of Hepatology

Issue

Hepatology Research

Early View (Online Version of Record published before inclusion in an issue)

ABSTRACT

Aim:  To evaluate the association between liver stiffness measured by

transient elastography (FibroScan) and the efficacy of long-term nucleoside

analog (NA) treatment for patients with chronic hepatitis B.

Methods:  Study 1: Forty-four chronic HBV patients had liver stiffness

measured by FibroScan and underwent liver biopsy. Study 2: Group A: 22 patients

started NA treatment at entry and FibroScan was done annually for 3 years. Group

B: 23 patients started NA treatment prior to pretreatment FibroScan measurement,

and FibroScan was done for from 3 to 5 years after the start of NA treatment.

Results:  Study 1: The FibroScan values were significantly correlated with

fibrosis stage (r = 0.672, P < 0.0001). Optimal cutoff of FibroScan values were

6.1 kPa for ≥ F1, 6.3 kPa for ≥ F2, 8.9 kPa for ≥ F3 and 12.0 kPa for F4.

Study 2: For Group A, the baseline median FibroScan value was 8.2 kPa. FibroScan

values significantly decreased annually for 3 years after the start of NA

treatment (6.4 kPa, 5.8 kPa and 5.3 kPa at years 1, 2 and 3, respectively). For

Group B, the FibroScan values did not significantly improve over the 3 years

after the start of NA treatment.

Conclusions:  Liver stiffness, measured by transient elastography, of chronic

hepatitis B patients treated with NA showed a rapid decline in the first 3 years

followed by a more steady transition for from 3 to 5 years irrespective of long

term virological effect.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2011.00869.x/abstract

Longitudinal assessment of liver stiffness by transient elastography for chronic

hepatitis B patients treated with nucleoside analog

Eiichi Ogawa1, Norihiro Furusyo1,2,*, Masayuki Murata1, Hachiro Ohnishi1,

Kazuhiro Toyoda1, Hiroaki Taniai1, Takeshi Ihara2, Hiroaki Ikezaki2, Takeo

Hayashi2, Mosaburo Kainuma1, Jun Hayashi1,2

Article first published online: 15 SEP 2011

DOI: 10.1111/j.1872-034X.2011.00869.x

© 2011 The Japan Society of Hepatology

Issue

Hepatology Research

Early View (Online Version of Record published before inclusion in an issue)

ABSTRACT

Aim:  To evaluate the association between liver stiffness measured by

transient elastography (FibroScan) and the efficacy of long-term nucleoside

analog (NA) treatment for patients with chronic hepatitis B.

Methods:  Study 1: Forty-four chronic HBV patients had liver stiffness

measured by FibroScan and underwent liver biopsy. Study 2: Group A: 22 patients

started NA treatment at entry and FibroScan was done annually for 3 years. Group

B: 23 patients started NA treatment prior to pretreatment FibroScan measurement,

and FibroScan was done for from 3 to 5 years after the start of NA treatment.

Results:  Study 1: The FibroScan values were significantly correlated with

fibrosis stage (r = 0.672, P < 0.0001). Optimal cutoff of FibroScan values were

6.1 kPa for ≥ F1, 6.3 kPa for ≥ F2, 8.9 kPa for ≥ F3 and 12.0 kPa for F4.

Study 2: For Group A, the baseline median FibroScan value was 8.2 kPa. FibroScan

values significantly decreased annually for 3 years after the start of NA

treatment (6.4 kPa, 5.8 kPa and 5.3 kPa at years 1, 2 and 3, respectively). For

Group B, the FibroScan values did not significantly improve over the 3 years

after the start of NA treatment.

Conclusions:  Liver stiffness, measured by transient elastography, of chronic

hepatitis B patients treated with NA showed a rapid decline in the first 3 years

followed by a more steady transition for from 3 to 5 years irrespective of long

term virological effect.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2011.00869.x/abstract

Longitudinal assessment of liver stiffness by transient elastography for chronic

hepatitis B patients treated with nucleoside analog

Eiichi Ogawa1, Norihiro Furusyo1,2,*, Masayuki Murata1, Hachiro Ohnishi1,

Kazuhiro Toyoda1, Hiroaki Taniai1, Takeshi Ihara2, Hiroaki Ikezaki2, Takeo

Hayashi2, Mosaburo Kainuma1, Jun Hayashi1,2

Article first published online: 15 SEP 2011

DOI: 10.1111/j.1872-034X.2011.00869.x

© 2011 The Japan Society of Hepatology

Issue

Hepatology Research

Early View (Online Version of Record published before inclusion in an issue)

ABSTRACT

Aim:  To evaluate the association between liver stiffness measured by

transient elastography (FibroScan) and the efficacy of long-term nucleoside

analog (NA) treatment for patients with chronic hepatitis B.

Methods:  Study 1: Forty-four chronic HBV patients had liver stiffness

measured by FibroScan and underwent liver biopsy. Study 2: Group A: 22 patients

started NA treatment at entry and FibroScan was done annually for 3 years. Group

B: 23 patients started NA treatment prior to pretreatment FibroScan measurement,

and FibroScan was done for from 3 to 5 years after the start of NA treatment.

Results:  Study 1: The FibroScan values were significantly correlated with

fibrosis stage (r = 0.672, P < 0.0001). Optimal cutoff of FibroScan values were

6.1 kPa for ≥ F1, 6.3 kPa for ≥ F2, 8.9 kPa for ≥ F3 and 12.0 kPa for F4.

Study 2: For Group A, the baseline median FibroScan value was 8.2 kPa. FibroScan

values significantly decreased annually for 3 years after the start of NA

treatment (6.4 kPa, 5.8 kPa and 5.3 kPa at years 1, 2 and 3, respectively). For

Group B, the FibroScan values did not significantly improve over the 3 years

after the start of NA treatment.

Conclusions:  Liver stiffness, measured by transient elastography, of chronic

hepatitis B patients treated with NA showed a rapid decline in the first 3 years

followed by a more steady transition for from 3 to 5 years irrespective of long

term virological effect.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1872-034X.2011.00869.x/abstract

Longitudinal assessment of liver stiffness by transient elastography for chronic

hepatitis B patients treated with nucleoside analog

Eiichi Ogawa1, Norihiro Furusyo1,2,*, Masayuki Murata1, Hachiro Ohnishi1,

Kazuhiro Toyoda1, Hiroaki Taniai1, Takeshi Ihara2, Hiroaki Ikezaki2, Takeo

Hayashi2, Mosaburo Kainuma1, Jun Hayashi1,2

Article first published online: 15 SEP 2011

DOI: 10.1111/j.1872-034X.2011.00869.x

© 2011 The Japan Society of Hepatology

Issue

Hepatology Research

Early View (Online Version of Record published before inclusion in an issue)

ABSTRACT

Aim:  To evaluate the association between liver stiffness measured by

transient elastography (FibroScan) and the efficacy of long-term nucleoside

analog (NA) treatment for patients with chronic hepatitis B.

Methods:  Study 1: Forty-four chronic HBV patients had liver stiffness

measured by FibroScan and underwent liver biopsy. Study 2: Group A: 22 patients

started NA treatment at entry and FibroScan was done annually for 3 years. Group

B: 23 patients started NA treatment prior to pretreatment FibroScan measurement,

and FibroScan was done for from 3 to 5 years after the start of NA treatment.

Results:  Study 1: The FibroScan values were significantly correlated with

fibrosis stage (r = 0.672, P < 0.0001). Optimal cutoff of FibroScan values were

6.1 kPa for ≥ F1, 6.3 kPa for ≥ F2, 8.9 kPa for ≥ F3 and 12.0 kPa for F4.

Study 2: For Group A, the baseline median FibroScan value was 8.2 kPa. FibroScan

values significantly decreased annually for 3 years after the start of NA

treatment (6.4 kPa, 5.8 kPa and 5.3 kPa at years 1, 2 and 3, respectively). For

Group B, the FibroScan values did not significantly improve over the 3 years

after the start of NA treatment.

Conclusions:  Liver stiffness, measured by transient elastography, of chronic

hepatitis B patients treated with NA showed a rapid decline in the first 3 years

followed by a more steady transition for from 3 to 5 years irrespective of long

term virological effect.